Filtered By:
Drug: Dexamethasone
This page shows you your search results in order of date. This is page number 12.
Order by Relevance | Date
Total 6433 results found since Jan 2013.
Chemotherapy-Induced Peripheral Neuropathy Impacts Quality Of Life And Activities Of Daily Living Of Brazilian Multiple Myeloma Patients
CONCLUSION: MM patients showed a high frequency of CIPN, which affected ADL and impaired HRQoL. Early and accurate detection of CIPN and dose management in patients with thalidomide and bortezomib-based regimens should be performed to provide better treatment outcomes and avoid permanent disabilities.PMID:37592770 | DOI:10.2174/1574886318666230817162424
Source: Current Drug Safety - August 18, 2023 Category: Drugs & Pharmacology Authors: Paula Lana de Miranda Drummond Roberta M árcia Marques Dos Santos L ívia Pena Silveira J éssica Soares Malta Adriano Max Moreira Reis Naiane Lima Costa Roberta Oliveira de Paula E Silva Evandro Maranh ão Fagundes Cristiane Aparecida Menezes de P ádua Source Type: research
At what point are we on the way to optimally treat multiple myeloma patients over 75 years of age in 2023?
Adv Clin Exp Med. 2023 Aug 14. doi: 10.17219/acem/168685. Online ahead of print.ABSTRACTSeveral novel drugs for multiple myeloma, including monoclonal and bispecific antibodies, immunomodulatory agents, and newer-generation proteasome inhibitors, have been introduced over the last decade. Based on the results of randomized clinical trials, the drugs have been incorporated into current treatment recommendations, with the most substantial changes observed in patients under the age of 75. However, new therapeutic options have been indirectly proposed for patients over 75, despite the lack of conclusive data from randomized pr...
Source: Adv Data - August 17, 2023 Category: Epidemiology Authors: Agata Tyczy ńska Jan Zaucha Source Type: research
Four New Stilbene Derivatives Isolated from Gnetum latifolium var. funiculare Markgr. and Their Inhibition of NO Production in LPS-activated RAW264.7 Cells
Chem Biodivers. 2023 Aug 17:e202301166. doi: 10.1002/cbdv.202301166. Online ahead of print.ABSTRACTGnetum latifolium var. funiculare Markgr. is a medicinal plant and widely distributed in mountainous areas of Vietnam. Phytochemical investigation on the trunks of this plant afforded eight stilbene derivatives (1-8) including for new compounds (1-4). Their structures were determined based on extensive analyses of HR-ESI-MS, 1D and 2D NMR spectra. Among the isolates, compounds 1-3 showed moderate NO production inhibition in LPS-activated RAW264.7 cells with the IC50 values ranging from 46.81 to 68.10 μM, compounds 4 and 6 sh...
Source: Chemistry and Biodiversity - August 17, 2023 Category: Biochemistry Authors: Trinh Thi Thuy Nguyen Thi Thu Hoa Nguyen Thi Thuy Linh Ba Thi Cham Nguyen Thi Hoang Anh Nguyen Tuan Hiep Sabrina Adorisio Domenico V Delfino Ngo Anh Bang Bui Huu Tai Phan Van Kiem Source Type: research
High Prevalence of Frailty in Patients with Adrenal Adenomas and Adrenocortical Hormone Excess - a cross-sectional multi-centre study with prospective enrolment
CONCLUSION: While frailty prevalence was highest in patients with adrenocortical hormone excess, even patients with NFA demonstrated an increased prevalence compared to the referent population. Future longitudinal studies are needed to evaluate the impact of various management strategies on frailty.PMID:37590964 | DOI:10.1093/ejendo/lvad113
Source: European Journal of Endocrinology - August 17, 2023 Category: Endocrinology Authors: Prerna Dogra Lana Šambula Jasmine Saini Karthik Thangamuthu Shobana Athimulam Danae A Delivanis Dimitra A Baikousi Rohit Nathani Catherine D Zhang Natalia Genere Zara Salman Adina F Turcu Urszula Ambroziak Raul Gregg Garcia Sara J Achenbach Elizabeth J A Source Type: research
At what point are we on the way to optimally treat multiple myeloma patients over 75 years of age in 2023?
Adv Clin Exp Med. 2023 Aug 14. doi: 10.17219/acem/168685. Online ahead of print.ABSTRACTSeveral novel drugs for multiple myeloma, including monoclonal and bispecific antibodies, immunomodulatory agents, and newer-generation proteasome inhibitors, have been introduced over the last decade. Based on the results of randomized clinical trials, the drugs have been incorporated into current treatment recommendations, with the most substantial changes observed in patients under the age of 75. However, new therapeutic options have been indirectly proposed for patients over 75, despite the lack of conclusive data from randomized pr...
Source: Adv Data - August 17, 2023 Category: Epidemiology Authors: Agata Tyczy ńska Jan Zaucha Source Type: research
High Prevalence of Frailty in Patients with Adrenal Adenomas and Adrenocortical Hormone Excess - a cross-sectional multi-centre study with prospective enrolment
CONCLUSION: While frailty prevalence was highest in patients with adrenocortical hormone excess, even patients with NFA demonstrated an increased prevalence compared to the referent population. Future longitudinal studies are needed to evaluate the impact of various management strategies on frailty.PMID:37590964 | DOI:10.1093/ejendo/lvad113
Source: European Journal of Endocrinology - August 17, 2023 Category: Endocrinology Authors: Prerna Dogra Lana Šambula Jasmine Saini Karthik Thangamuthu Shobana Athimulam Danae A Delivanis Dimitra A Baikousi Rohit Nathani Catherine D Zhang Natalia Genere Zara Salman Adina F Turcu Urszula Ambroziak Raul Gregg Garcia Sara J Achenbach Elizabeth J A Source Type: research
Effects of pharmacological doses of niacin on subacute glucocorticoid-induced testicular damage in rats
In conclusion, niacin administration at pharmacological doses dose-dependently ameliorates the destructive effects of dexamethasone on sperm motility, Johnsen score, and testicular cell apoptosis in rats with the latter can be considered a decisive mechanism for its positive effects on testis.PMID:37589322 | DOI:10.1002/prp2.1128
Source: Cell Research - August 17, 2023 Category: Cytology Authors: E Azimi Zangabad Tahoora Shomali L Roshangar Source Type: research
Isatuximab plus carfilzomib and dexamethasone in patients with early versus late relapsed multiple myeloma: IKEMA subgroup analysis
Haematologica. 2023 Aug 16. doi: 10.3324/haematol.2023.283073. Online ahead of print.ABSTRACTPatients with multiple myeloma (MM) who experience early relapse within 12 months of therapy initiation are considered functional high-risk and represent an unmet need, needing better therapies to improve outcomes. The final IKEMA (NCT03275285) progression-free survival (PFS) analysis confirmed the significant PFS improvement reported at interim analysis with isatuximab (Isa) plus carfilzomib and dexamethasone (Kd; Isa-Kd) versus Kd in patients with relapsed MM (updated median PFS: 35.7 vs. 19.2 months; HR=0.58 [95.4% CI: 0.42-0.79...
Source: Haematologica - August 16, 2023 Category: Hematology Authors: Thierry Facon Philippe Moreau Ross Baker Chang-Ki Min Xavier Leleu Mohamad Mohty Lionel Karlin Nicole M Armstrong Christina Tekle Sandrine Schwab Marie-Laure Risse Thomas Martin Source Type: research
